Want to join the conversation?
In FY17, $PDCO anticipates stable markets in both dental and animal health segments. The company reaffirmed its FY17 guidance range for adjusted earnings from continuing operations of $2.60-2.70 per diluted share. Annual guidance range includes a pretax $25MM step up in operating expense associated with the ERP implementation, the company said.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.